ERIS Lifesciences Ltd management interview: Eris Lifesciences Reports 13% Revenue Growth In Q2FY27; Margin Slips | CNBC TV18
CNBC-TV18, 2026-10-27. Video: https://www.youtube.com/watch?v=w4JbLAuGeiI
- Margin outlook: Domestic branded formulations margins are expected at 36 to 37% on the DBF in FY27, with consolidated blended margins close to 35%. Bakshi expects gross margins to improve by 150 to 200 basis points in the next half as production from Eris’s own facility increases, supporting EBITDA margins.
- Semaglutide demand: Eris has higher teens quarterly sales, ranks number 1 in units and prescriptions and number 2 in value, partly because it offers a vial SKU for access. Bakshi said the market is in an experience phase and could double next year as it moves toward consolidation over another 6-9 months.
- Export outlook: Exports contribute less than 10% of sales and less than that of profit; a GMP issue is holding the business around current levels while remediation proceeds. A new block is expected to enter PV batches in March-April, and a better run next year depends on its approval and restoration of GMP status.
- Growth and debt: Eris reported around 13% growth this quarter, matching the prior quarter’s ballpark, and expects to maintain that number despite weaker international performance. Bakshi expects another ₹150-200 crore of debt reduction in H2 and significant reduction next year as the capex cycle wanes.